Share

Latest Documents


  • 14-March-2023

    English

    Series on Testing and Assessment: publications by number

    The OECD has been developing guidance documents and tools for the use of alternative methods such as (Q)SAR, chemical categories and Adverse Outcome Pathways (AOPs) as a part of Integrated Approaches for Testing and Assessment (IATA). The objective is to increase experience with the use of IATA by developing case studies, which constitute examples of predictions that are fit for regulatory use.

    Related Documents
  • 13-March-2023

    English

    OECD work on in vitro assays for developmental neurotoxicity

    Discover OECD work on in vitro assays for developmental neurotoxicity

    Related Documents
  • 28-February-2023

    English

    Section 4: Health Effects

    Interested parties are invited to send their comments on the Draft Updated Performance Standards for in vitro reconstructed human cornea-like epithelium (RHCE) Test Methods for eye hazard identification by 28 February 2023.

    Related Documents
  • 13-February-2023

    English

    Webinar Series on Emerging Science to Improve Chemical Safety

    Emerging technologies of common interest will offer opportunities to develop, standardise and harmonise novel methods and approaches into Test Guidelines. This workshop aimed to identify where practice and process could evolve for the OECD Test Guidelines Programme to remain relevant and useful to support country chemicals regulations.

    Related Documents
  • 9-February-2023

    English

    Draft Guidance and Review Documents/Monographs

    Interested parties are invited to send their comments on the Draft Test Guideline: Determination of the Hydrophobicity Index of Nanomaterials Through an Affinity Measurement (Jan 2023) by 9 February 2023.

    Related Documents
  • 7-February-2023

    English

    Webinar Series on Testing and Assessment Methodologies

    7 February 2023 at 14:00-16:00 CET / 08:00-10:00 EST | This webinar will present the methods described in Test Guideline No. 125 to determine the size and size distributions of nanomaterial particles and fibres spanning from 1 nm to 1000 nm. During this webinar, you will be able to learn the use and limitation of this Test Guideline, as well as on the validation exercise that was done to support its development.

    Related Documents
  • 16-December-2022

    English

    Adverse Outcome Pathways, Molecular Screening and Toxicogenomics

    This new release includes four single AOPs and a network of five AOPs addressing various toxicological and ecotoxicological pathways.

    Related Documents
  • 11-October-2022

    English

    OECD Good Laboratory Practice: Frequently asked questions (FAQ)

    GLP issues raised by testing labs are covered in this comprehensive list of questions and answers, recently updated with questions related to: Test Facility organisation and personnel, Quality Assurance, Equipment and computerized systems, Test items, reference items and samples/specimens (Biologicals, GMOs, etc.), SOPs, Management of the study, Histopathology, Archives and E-Archives and Monitoring Test Facility compliance by GLP CMAs.

    Related Documents
  • 30-June-2022

    English

    Test No. 442D: In Vitro Skin Sensitisation - ARE-Nrf2 Luciferase Test Method

    The present Test Guideline addresses the human health hazard endpoint skin sensitisation, following exposure to a test chemical. Skin sensitisation refers to an allergic response following skin contact with the tested chemical, as defined by the United Nations Globally Harmonized System of Classification and Labelling of Chemicals (UN GHS). This Test Guideline (TG) provides an in vitro procedure (the ARE-Nrf2 luciferase test method) used for supporting the discrimination between skin sensitisers and non-sensitisers in accordance with the UN GHS. The second key event on the adverse outcome pathway leading to skin sensitisation takes place in the keratinocytes and includes inflammatory responses as well as gene expression associated with specific cell signalling pathways such as the antioxidant/electrophile response element (ARE)-dependent pathways. The test method described in this Test Guideline (ARE-Nrf2 luciferase test method) is proposed to address this second key event. The cell line contains the luciferase gene under the transcriptional control of a constitutive promoter fused with an ARE element from a gene that is known to be up-regulated by contact sensitisers. The luciferase signal reflects the activation by sensitisers of endogenous Nrf2 dependent genes. This allows quantitative measurement (by luminescence detection) of luciferase gene induction, using well established light producing luciferase substrates, as an indicator of the activity of the Nrf2 transcription factor in cells following exposure to electrophilic test substances. There are currently two in vitro ARE-Nrf2 luciferase test method covered by this Test Guideline: the KeratinoSensTM test method and the LuSens test method. Performance standards have been developed to enable the validation of similar test methods.
  • 1-December-2021

    English

    Good Laboratory Practice (GLP)

    Read the countries' response to address the challenges posed by COVID-19 to GLP test facilities.

    Related Documents
  • 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 > >>